Insulin-like growth factor 2 mRNA-binding protein 1 promotes cell proliferation via activation of AKT and is directly targeted by microRNA-494 in pancreatic cancer

Figure 2 Knockdown of insulin-like growth factor 2 mRNA-binding protein 1 inhibits pancreatic cancer cell proliferation in vitro. A-C: Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) levels were determined by quantitative reverse transcription polymerase chain reaction analysis 48 h after transfection; D-F: IGF2BP1 levels were determined by Western blot analysis 48 h after transfection; G-I: CCK-8 assays were performed to compare the proliferation of IGF2BP1 knockdown or overexpressing cells vs the control cells. GAPDH served as the loading control. All data are expressed as the mean ± standard deviation from three independent experiments at least and P < 0.05 was considered statistically significant. ^aP < 0.05 vs siRNA group; ^bP < 0.05 vs normal group; ^cP < 0.01 vs IGF2BP1-OE group; ^dP < 0.05 vs siRNA at day 3; ^eP < 0.01 vs siRNA at day 4; ^fP < 0.01 vs siRNA at day 5; ^gP < 0.01 vs siRNA at day 3; ^hP < 0.01 vs siRNA at day 4; ⁱP < 0.01 vs siRNA at day 5; ^jP < 0.05 vs siRNA at day 3; ^kP < 0.01 vs siRNA at day 4; ^lP < 0.01 vs siRNA at day 5. IGF2BP1: Insulin-like growth factor 2 mRNA-binding protein 1.